Characterization of AAV-mediated dorsal root ganglionopathy

被引:42
|
作者
Buss, Nicholas [1 ]
Lanigan, Lisa [2 ]
Zeller, Jillynne [3 ]
Cissell, Derek [4 ]
Metea, Monica [5 ]
Adams, Eric [2 ]
Higgins, Mikayla [1 ]
Kim, Kwi Hye [1 ]
Budzynski, Ewa [1 ]
Yang, Lin [1 ]
Liu, Ye [1 ]
Butt, Mark [2 ]
Danos, Olivier [1 ]
Fiscella, Michele [1 ]
机构
[1] REGENXBIO, 9804 Med Ctr Dr, Rockville, MD 20850 USA
[2] StageBio, Frederick, MD 21701 USA
[3] Northern Biomed Res, Spring Lake, MI 49456 USA
[4] Invicro, Needham, MA 02494 USA
[5] Preclin Elect Consulting, Mattapoisett, MA 02739 USA
关键词
ADENOASSOCIATED VIRUS; GENE-THERAPY; TOXICOLOGY; MRI;
D O I
10.1016/j.omtm.2022.01.013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recent studies in non-human primates administered recombinant adeno-associated viruses (rAAVs) have shown lesions in the dorsal root ganglia (DRG) of unknown pathogenesis. In this study, rAAV9s manufactured using different purification methods alongside a non-expressing Null AAV9 vector was administered to groups of cynomolgus monkeys followed by neuropathological evaluation after 4 weeks. Lesions, including neuronal degeneration, increased cellularity, and nerve fiber degeneration, were observed in the DRG, regardless of purification methods. Animals did not develop any neurological signs throughout the study, and there was no loss of function observed in neuro-electrophysiological endpoints or clear effects on intraepidermal nerve fiber density. However, magnetic resonance imaging (MRI) of animals with axonopathy showed an increase in short tau inversion recovery (STIR) intensity and decrease in fractional anisotropy. In animals administered the Null AAV9 vector, DRG lesions were not observed despite vector DNA being detected in the DRG at levels equivalent to or greater than rAAV9-treated animals. This study further supports that DRG toxicity is associated with transgene overexpression in DRGs, with particular sensitivity at the lumbar and lumbosacral level. The data from this study also showed that the nerve fiber degeneration did not correlate with any functional effect on nerve conduction but was detectable by MRI.
引用
收藏
页码:342 / 354
页数:13
相关论文
共 50 条
  • [1] Circulating neurofilaments to track dorsal root ganglion toxicity risks with AAV-mediated gene therapy
    Farrar, Michelle A.
    Groen, Ewout
    Alves, Christiano R. R.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2022, 26 : 96 - 97
  • [2] A Rare Cause of Dorsal Root Ganglionopathy
    Sexton, K.
    O'Callaghan, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S70 - S71
  • [3] Characterization of Dorsal Root Ganglionopathy Following Intrathecal Delivery of High-Dose AAV9.CAG.EGFP Vector to Adult Rats
    Dzhashiashvili, Yulia
    Kelly, Brian M.
    Gibbs, Greglynn D.
    Wicks, Joan
    Engel, Esteban A.
    Ramsburg, Elizabeth
    MOLECULAR THERAPY, 2024, 32 (04) : 875 - 875
  • [4] Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS
    Szmulewicz, David J.
    McLean, Catriona A.
    Rodriguez, Michael L.
    Chancellor, Andrew M.
    Mossman, Stuart
    Lamont, Duncan
    Roberts, Leslie
    Storey, Elsdon
    Halmagyi, G. Michael
    NEUROLOGY, 2014, 82 (16) : 1410 - 1415
  • [5] Anti-Yo positive dorsal root ganglionopathy
    McNamara, Patricia
    Costelloe, Lisa
    Langan, Yvonne
    Redmond, Janice
    JOURNAL OF NEUROLOGY, 2011, 258 (03) : 519 - 520
  • [6] A RARE CAUSE FOR DORSAL ROOT GANGLIONOPATHY WITH RESPONSE TO IMMUNOMODULATION
    Rao, Dasappaiah Ganesh
    Alix, James
    Ali, Rokiahmah
    Slater, David
    Messenger, Andrew
    Hadjivassiliou, Marios
    MUSCLE & NERVE, 2014, 50 (04) : 646 - 646
  • [7] The Notorious Drg: A Delayed Diagnosis of Dorsal Root Ganglionopathy
    Frawley, Rebecca
    Aspromonte, Christopher
    Undavia, Anishee
    ANNALS OF NEUROLOGY, 2023, 94 : S250 - S251
  • [8] Anti-Yo positive dorsal root ganglionopathy
    Patricia McNamara
    Lisa Costelloe
    Yvonne Langan
    Janice Redmond
    Journal of Neurology, 2011, 258 : 519 - 520
  • [9] Characterization of the role of the transcriptional regulator Senataxin on AAV-mediated transgene expression
    Isola, S.
    Gomez Moreno, A.
    Herrero Martinez, D.
    Vales, A.
    Olague, C.
    Garaigorta, U.
    Gonzalez Aseguinolaza, G.
    Unzu, C.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A70 - A70
  • [10] AAV-Mediated Gene Therapy for Atherosclerosis
    Michael Lehrke
    Corinna Lebherz
    Current Atherosclerosis Reports, 2014, 16